Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Np4.0
Noopept – Forschung
Überwiegend Mechanismus / Beobachtung
12 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Noopept sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus mittelwertigen randomisierten Studien, veröffentlicht 2007–2020 mit einer typischen Studiengröße von 60 Teilnehmenden.
Basierend auf 12 Studien · 3 RCTs · 120 Teilnehmende insgesamt
Konfidenz
Mittlere Konfidenz
Nach Outcome
Cognitive functionFördert die Gedächtniskonsolidierung und den Abruf durch Stimulation von BDNF und NGF · 1-2 Wochen
Überwiegend Mechanismus / Beobachtung7 Studien
Neuroprotection & brain agingNeuroprotektives Peptid mit NGF/BDNF-Wirkung · 4-8 Wochen
Überwiegend Mechanismus / Beobachtung7 Studien
Anxiety & stressMilde angstlösende Wirkung über den Metaboliten Cycloprolylglycin · 2-4 Wochen
Überwiegend Mechanismus / Beobachtung4 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung3 Studien
Heart & blood pressure
Zu wenige bewertete Studien2 Studien
Energy & fatigue
Zu wenige bewertete Studien1 Studie
Safety profile
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 7 Studien mit messbaren Effekten gezogen
Untersuchte Personen
120
typische Studie: 60 Personen
Stärkste Designs
3
0 gepoolt, 3 randomisiert
Untersuchte Populationen
Drug development study1
Healthy volunteers1
PC12 cells (AD-related cellular model)1
Rats1
Ältere Forschungsbasis
Neueste Studie von 2020
200720132020
1Dipeptide drug design and developmentSystematische ÜbersichtCited 10×2018
Gudasheva TA et al. · Current pharmaceutical design (2018)
The latter usually corresponds to a beta-turn of some regulatory peptide.
The second approach represents the design of tripeptoide mimetic of the beta-turn of regulatory peptide or protein.
The results of the studies, which led to the discovery of endogenous prototypes of the known non-peptide drugs piracetam and sulpiride, are presented herein.
The results have demonstrated that noopept, used in dose 20 mg daily during 2 months, improves cognitive functions in stroke patients and has a high level of safety.
Amelin AV et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2011)
An analysis of MMSE scores and lateral and categorical associations revealed the significant improvement of cognitive functions after 2 months in patients of the main group compared to the controls.
Cognitive functions were assessed before and after treatment using neuropsychological tests.
The global assessment of efficacy revealed the mild improvement in the main group while no changes were found in the control group.
3RCTCited 4×2008
The EEG changes in posttraumatic brain lesion were less typical.
Bochkarev VK et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2008)
The analysis of frequency and spatial structure of EEG changes reveals that noopept exerts a nonspecific activation and anxyolytic effect.
The differences in EEG changes depending on the brain pathology were found.
The EEG indices of nootropic effect of the drug were most obvious in cerebral vascular diseases.
4Physical and psychological efficiency under changing environmental conditionsRCT2007
Therefore, all the drugs studied (vinpotropil, cortexin, noopept and dilept) can be recommended as the agents producing activation, support and recovery of the physical and psychological efficiency under rapidly changing environment conditions.
Shabanov PD et al. · Eksperimental'naia i klinicheskaia farmakologiia (2007)
Noopept, affecting positively a psychological component of the functional state, can be used for rapid adaptation to both cold and hot climate.
In the hot climate, noopept also enhanced the physical work capacity.
Therefore, all the drugs studied (vinpotropil, cortexin, noopept and dilept) can be recommended as the agents producing activation, support and recovery of the physical and psychological efficiency under rapidly changing environment conditions.
5Neuroprotective effect against Aβ-induced cellular damageBeobachtungsstudieCited 15×2014
Taken together, these data provide evidence that novel cognitive enhancer noopept protects PC12 cell against deleterious actions of Aβ through inhibiting the oxidative damage and calcium overload as well as suppressing the mitochondrial apoptotic pathway.
Ostrovskaya RU et al. · Journal of biomedical science (2014)
Taken together, these data provide evidence that novel cognitive enhancer noopept protects PC12 cell against deleterious actions of Aβ through inhibiting the oxidative damage and calcium overload as well as suppressing the mitochondrial apoptotic pathway.
Moreover, neuroprotective properties of noopept likely include its ability to decrease tau phosphorylation and to restore the altered morphology of PC12 cells.
Therefore, this nootropic dipeptide is able to positively affect not only common pathogenic pathways but also disease-specific mechanisms underlying Aβ-related pathology.
It was revealed that the effect of noopept is accompanied by changes in gene expression, which belong to different metabolic pathways and are controlled by the transcription factor HIF-1.
Zainullina LF et al. · Doklady. Biochemistry and biophysics (2020)
The effect of noopept (N-phenylacetyl-L-prolyl-glycine ethyl ester) on the DNA-binding activity of HIF-1 in SH-SH5Y cells and the mechanisms of stabilization of this transcription factor were studied in vitro.
Noopept was shown to increase both the basal DNA-binding activity of HIF-1 and the activity induced by various hypoxia mimetics.
The mechanism of stabilization of the oxygen-sensitive HIF1α subunit by noopept involves the inhibition of HIF-1 prolyl hydroxylase, which is indirectly indicated by the data obtained using the ODD-Luc reporter, and the positive effect on the level of the HIF1α protein.
These data suggest that Noopept does not stimulate cell growth.
Zainullina LF et al. · Bulletin of experimental biology and medicine (2019)
The previously established multifactorial mechanism of action of the drug includes enhancement of neurotrophin NGF and BDNF expression and increase in HIF-1 activity.
The possible mitogenic action of Noopept was estimated by its effect on cell proliferation.
Noopept did not affect cell distribution over G1, S, G2 cell cycle phases and the relative level of proliferation marker Ki-67 in the cell lines under study.
8NGF and BDNF mRNA expression in hippocampusTierstudie2008
We showed that the nootropic drug increases expression of neurotrophic factors in the hippocampus.
Ostrovskaya RU et al. · Bulletin of experimental biology and medicine (2008)
In the hippocampus, expression of mRNA for both neurotrophins increased after acute administration of Noopept.
Chronic treatment with Noopept was not followed by the development of tolerance, but even potentiated the neurotrophic effect.
Our results are consistent with the hypothesis that neurotrophin synthesis in the hippocampus determines cognitive function, particularly in consolidation and delayed memory retrieval.
The treatment promoted functional normalization of vegetative nervous system and antioxidative systems, reduced manifestations of anxiety, decreased frequency of adverse neuro- and cardiotoxic responses to antituberculous drugs.
Mordyk AV et al. · Klinicheskaia meditsina (2009)
The study evaluated clinical efficiency of noopept used to prevent adverse side effects of antituberculous agents.
It included 60 patients with newly diagnosed respiratory tuberculosis.
Those in group 1 (n = 30) received 10 mg of noopept twice daily during the first month.
10Cognitive function improvementBeobachtungsstudieCited 9×2009
This observational examined the effects of Noopept.
Neznamov GG et al. · Neuroscience and behavioral physiology (2009)